5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cet article présente les recommandations, issues de la 5ème conférence internationale de consensus organisée par l'"European School of Oncology" et l'"European Society for Medical Oncology", concernant la prise en charge d'un cancer du sein de stade avancé
For the purpose of ABC guidelines, advanced breast cancer (ABC) comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). Advanced/metastatic breast cancer remains a virtually incurable disease, with a median overall survival (OS) of about 3 years and a 5-year survival rate of around 25%, even in countries without major accessibility problems. Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC. ABC is a treatable disease with several available therapies and many others in development. However, their impact on survival and quality of life (QoL) of ABC patients has been slow
and different for de novo versus recurrent ABC, with the latter becoming much harder to treat in recent years.
Annals of Oncology , article en libre accès, 2020